|
|
| Line 1: |
Line 1: |
| {{Drugbox | | __NOTOC__ |
| | Verifiedfields = changed
| | {{CMG}} |
| | Watchedfields = changed
| |
| | verifiedrevid = 447915116
| |
| | IUPAC_name = 1-{[(6''R'',7''R'')-7-[(2''E'')-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetamido]-2-carboxylato-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl]methyl}-5''H'',6''H'',7''H''-cyclopenta[''b'']pyridin-1-ium
| |
| | image =
| |
|
| |
|
| <!--Clinical data-->
| | ==Overview== |
| | tradename =
| |
| | Drugs.com = {{drugs.com|international|cefpirome}}
| |
| | pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| |
| | pregnancy_US = <!-- A / B / C / D / X -->
| |
| | pregnancy_category =
| |
| | legal_AU = <!-- Unscheduled / S2 / S3 / S4 / S5 / S6 / S7 / S8 / S9 -->
| |
| | legal_CA = <!-- / Schedule I, II, III, IV, V, VI, VII, VIII -->
| |
| | legal_UK = <!-- GSL / P / POM / CD / Class A, B, C -->
| |
| | legal_US = <!-- OTC / Rx-only / Schedule I, II, III, IV, V -->
| |
| | legal_status =
| |
| | routes_of_administration =
| |
|
| |
|
| <!--Pharmacokinetic data-->
| | Cefpirome is a fourth-generation [[cephalosporin]] which is considered highly active against [[Gram-positive bacteria]] and [[Gram-negative bacteria]] including ''[[Pseudomonas aeruginosa]]''. It is marketed under the brand name of CEFROM by Sanofi Aventis group India. |
| | bioavailability =
| |
| | protein_bound =
| |
| | metabolism =
| |
| | elimination_half-life =
| |
| | excretion =
| |
|
| |
|
| <!--Identifiers-->
| | ==Category== |
| | CAS_number_Ref = {{cascite|correct|??}}
| | |
| | CAS_number = 84957-29-9
| | Cephalosporin, Fourth-Generation |
| | ATC_prefix = J01
| | |
| | ATC_suffix = DE02
| | ==Mechanism of Action== |
| | PubChem = 6917674
| |
| | DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| |
| | DrugBank =
| |
| | UNII_Ref = {{fdacite|correct|FDA}}
| |
| | UNII = S72Q2F09HY
| |
| | KEGG_Ref = {{keggcite|correct|kegg}}
| |
| | KEGG = D07649
| |
| | ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}
| |
| | ChemSpiderID = 23089536
| |
| | smiles = CON=C(c1csc(n1)N)C(=O)NC2C3N(C2=O)C(=C(CS3)C[n+]4cccc5c4CCC5)C(=O)[O-]
| |
| | InChI = 1/C22H22N6O5S2/c1-33-26-15(13-10-35-22(23)24-13)18(29)25-16-19(30)28-17(21(31)32)12(9-34-20(16)28)8-27-7-3-5-11-4-2-6-14(11)27/h3,5,7,10,16,20H,2,4,6,8-9H2,1H3,(H3-,23,24,25,29,31,32)/b26-15-/t16-,20+/m1/s1
| |
| | InChIKey = DKOQGJHPHLTOJR-XECLGWKCBP
| |
| | StdInChI_Ref = {{stdinchicite|changed|chemspider}}
| |
| | StdInChI = 1S/C22H22N6O5S2/c1-33-26-15(13-10-35-22(23)24-13)18(29)25-16-19(30)28-17(21(31)32)12(9-34-20(16)28)8-27-7-3-5-11-4-2-6-14(11)27/h3,5,7,10,16,20H,2,4,6,8-9H2,1H3,(H3-,23,24,25,29,31,32)/b26-15-/t16-,20+/m1/s1
| |
| | StdInChIKey_Ref = {{stdinchicite|changed|chemspider}}
| |
| | StdInChIKey = DKOQGJHPHLTOJR-XECLGWKCSA-N
| |
|
| |
|
| <!--Chemical data-->
| |
| | C=22 | H=22 | N=6 | O=5 | S=2
| |
| | molecular_weight = 514.58 g/mol
| |
| }}
| |
| __NOTOC__
| |
| {{CMG}}
| |
|
| |
|
| ==Overview== | | ==Spectrum of Bacterial Susceptibility and Resistance== |
| Cefpirome is a fourth-generation [[cephalosporin]]. Trade names include Cefrom, Keiten, Broact, Cefir. Cefpirome is considered highly active against [[Gram-negative bacteria]], including ''[[Pseudomonas aeruginosa]]'', and [[Gram-positive bacteria]]. It is marketed under the brand name of ''' CEFROM ''' by sanofi aventis group india .
| |
|
| |
|
| == Spectrum of Bacterial Susceptibility and Resistance ==
| |
| Currently, [[Bacteroides fragilis]], [[Enterococci]], [[Pseudomonas]] spp. and [[Staphylococci]] are resistant to Cefpirome Sulfate, and some [[Haemophilus]] spp. and [[Pneumococci]] have developed resistance to Cefpirome Sulfate to varying degrees.<ref>{{cite web|title=Cefpirome Sulfate spectrum of bacterial susceptibility and Resistance|url=http://www.toku-e.com/Assets/MIC/Cefpirome.pdf|accessdate= }}</ref> | | Currently, [[Bacteroides fragilis]], [[Enterococci]], [[Pseudomonas]] spp. and [[Staphylococci]] are resistant to Cefpirome Sulfate, and some [[Haemophilus]] spp. and [[Pneumococci]] have developed resistance to Cefpirome Sulfate to varying degrees.<ref>{{cite web|title=Cefpirome Sulfate spectrum of bacterial susceptibility and Resistance|url=http://www.toku-e.com/Assets/MIC/Cefpirome.pdf|accessdate= }}</ref> |
|
| |
|
| ==References== | | ==References== |
| | |
| {{Reflist|2}} | | {{Reflist|2}} |
|
| |
|
| [[Category:Antibiotics]] | | [[Category:Antibiotics]] |
| [[Category:Cephalosporin antibiotics]]
| |
| [[Category:Thiazoles]]
| |
| [[Category:Wikinfect]] | | [[Category:Wikinfect]] |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Cefpirome is a fourth-generation cephalosporin which is considered highly active against Gram-positive bacteria and Gram-negative bacteria including Pseudomonas aeruginosa. It is marketed under the brand name of CEFROM by Sanofi Aventis group India.
Category
Cephalosporin, Fourth-Generation
Mechanism of Action
Spectrum of Bacterial Susceptibility and Resistance
Currently, Bacteroides fragilis, Enterococci, Pseudomonas spp. and Staphylococci are resistant to Cefpirome Sulfate, and some Haemophilus spp. and Pneumococci have developed resistance to Cefpirome Sulfate to varying degrees.[1]
References